Bispham Barbara Harlin 4
4 · CRESCENT BIOPHARMA, INC. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Crescent BioPharma (CBIO) GC Barbara Bispham Sells 1,218 Shares
What Happened
- Barbara Bispham, General Counsel and Corporate Secretary of Crescent BioPharma (CBIO), sold 1,218 shares on June 22, 2026. The weighted-average sale price was $17.99, generating proceeds of approximately $21,912.
- This was a sale (not a purchase) and was executed to satisfy tax withholding related to the vesting of restricted stock units — not an independent investment decision.
Key Details
- Transaction date: June 22, 2026; Form 4 filed June 23, 2026 (timely filing).
- Transaction type: Sale (S); shares sold: 1,218; weighted-average price: $17.99; proceeds ≈ $21,912.
- Price range: shares sold in multiple trades at $16.88 to $18.86 (weighted average reported).
- Purpose/footnote: Shares were automatically sold to cover tax withholding for RSUs granted Dec 15, 2025; sales effected under a Rule 10b5-1 plan adopted Feb 25, 2026.
- Shares owned after transaction: Not disclosed in this Form 4.
Context
- These sales were tax-withholding dispositions following RSU vesting and were carried out under a preplanned 10b5-1 instruction — commonly considered routine and not necessarily indicative of the insider’s view on the company’s prospects.
- For retail investors: purchases are usually more informative about insider sentiment; routine tax-related sales like this are common and generally neutral in isolation.
Insider Transaction Report
Form 4
Bispham Barbara Harlin
See Remarks
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-06-22$17.99/sh−1,218$21,912→ 19,330 total
Footnotes (2)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Signature
/s/ Barbara Bispham|2026-06-23